ENDRA Life Sciences Inc
NASDAQ:NDRA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
ENDRA Life Sciences Inc
Cash Interest Paid
ENDRA Life Sciences Inc
Cash Interest Paid Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Interest Paid | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
ENDRA Life Sciences Inc
NASDAQ:NDRA
|
Cash Interest Paid
$55.9k
|
CAGR 3-Years
-2%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Boston Scientific Corp
NYSE:BSX
|
Cash Interest Paid
$319m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
1%
|
|
|
Edwards Lifesciences Corp
NYSE:EW
|
Cash Interest Paid
$20.2m
|
CAGR 3-Years
2%
|
CAGR 5-Years
0%
|
CAGR 10-Years
2%
|
|
|
Stryker Corp
NYSE:SYK
|
Cash Interest Paid
$582m
|
CAGR 3-Years
22%
|
CAGR 5-Years
14%
|
CAGR 10-Years
19%
|
|
|
Abbott Laboratories
NYSE:ABT
|
Cash Interest Paid
$545m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Cash Interest Paid
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
ENDRA Life Sciences Inc
Glance View
ENDRA Life Sciences, Inc. develops medical imaging technology. The company is headquartered in Ann Arbor, Michigan and currently employs 22 full-time employees. The company went IPO on 2017-06-28. The firm has developed a technology platform, Thermo Acoustic Enhanced Ultrasound (TAEUS), which is intended to enhance the capability of clinical ultrasound technology and support the diagnosis and treatment of various other medical conditions. Its TAEUS technology platform application focuses on quantifying fat in the liver and stage progression of non-alcoholic fatty liver disease (NAFLD), which untreated, can progress to Non-alcoholic Steatohepatitis (NASH), fibrosis, cirrhosis, and liver cancer. The firm's TAEUS platform has various clinical applications, such as tissue composition, temperature monitoring, vascular imaging, and tissue perfusion.
See Also
What is ENDRA Life Sciences Inc's Cash Interest Paid?
Cash Interest Paid
55.9k
USD
Based on the financial report for Dec 31, 2025, ENDRA Life Sciences Inc's Cash Interest Paid amounts to 55.9k USD.
What is ENDRA Life Sciences Inc's Cash Interest Paid growth rate?
Cash Interest Paid CAGR 3Y
-2%
Over the last year, the Cash Interest Paid growth was 75%. The average annual Cash Interest Paid growth rates for ENDRA Life Sciences Inc have been -2% over the past three years .
